✦ LIBER ✦

Phase II study of pemetrexed plus intermittent erlotinib combination therapy for pretreated advanced non-squamous non-small cell lung cancer with documentation of epidermal growth factor receptor mutation status

✍ Scribed by Minami, Seigo; Kijima, Takashi; Hamaguchi, Masanari; Nakatani, Takeshi; Koba, Taro; Takahashi, Ryo; Takeuchi, Yoshiko; Kida, Hiroshi; Nagatomo, Izumi; Yamamoto, Suguru; Tachibana, Isao; Komuta, Kiyoshi; Kawase, Ichiro

Book ID: 121986743
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 700 KB
Volume: 82
Category: Article
ISSN: 0169-5002
DOI: 10.1016/j.lungcan.2013.07.022

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II trial of erlotinib in patients

Phase II trial of erlotinib in patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations: additive analysis of pharmacokinetics

✍ Motoshima, Kohei; Nakamura, Yoichi; Sano, Kazumi; Ikegami, Yoji; Ikeda, Takaya; 📂 Article 📅 2013 🏛 Springer 🌐 English ⚖ 227 KB

A phase II trial of gefitinib as first-l

A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations

✍ Asahina, H; Yamazaki, K; Kinoshita, I; Sukoh, N; Harada, M; Yokouchi, H; Ishida, 📂 Article 📅 2006 🏛 Nature Publishing Group 🌐 English ⚖ 139 KB

Prospective phase II study of gefitinib

Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations

✍ Sugio, Kenji; Uramoto, Hidetaka; Onitsuka, Takamitsu; Mizukami, Makiko; Ichiki, 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 181 KB

Prospective Phase II Study of Gefitinib

Prospective Phase II Study of Gefitinib for Chemotherapy-Naive Patients With Advanced Non-Small-Cell Lung Cancer With Epidermal Growth Factor Receptor Gene Mutations

✍ Inoue, A. 📂 Article 📅 2006 🏛 American Society of Clinical Oncology 🌐 English ⚖ 262 KB

Phase I/II trial of vorinostat (SAHA) an

Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression

✍ Reguart, Noemi; Rosell, Rafael; Cardenal, Felipe; Cardona, Andres F.; Isla, Dolo 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 645 KB

Clinical significance of pretreatment se

Clinical significance of pretreatment serum amphiregulin and transforming growth factor-α, and an epidermal growth factor receptor somatic mutation in patients with advanced non-squamous, non-small cell lung cancer

✍ Katsuhiro Masago; Shiro Fujita; Yukimasa Hatachi; Akiko Fukuhara; Keiichiro Saku 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 175 KB